Member Info for a-2-b

https://www.gsk.com/en-gb/research/our-approach/open-innovation/targeting-the-immune-system-through-open-innovation/

Page reads similar to this paper too:

http://www.immupharma.co.uk/wp-content/uploads/2017/08/Autophagy-Muller-et-al.-Autoimm-Rev-2017.pdf

https://wallmine.com/lse/imm/officer/997921/stephane-mery

Can't see it

I'm guessing this is more relative to the US, hence why positive results were achieved from Europe.

https://www.benzinga.com/pressreleases/18/07/r12073984/analysis-of-over-1-000-systemic-lupus-erythematosus-patients-reveals-r

May very possibly have seen the bottom the 52 week low was a bit over exaggerated anyways. Fair retest as this level anyways.

Thanks for confirming that

Those machines are not cheap at all probably scaled back holding to be able to afford such a monster as well as having a healthy balance sheet for the company. The airport contract say if we get about a quarter of that amount in question (not even that) adding that to the current revenue stream there's no way we should be where we are the debt will be gone very soon at this rate when the influx begins.

Well I guess that explains why Bachmann had to sell some shares. Any fraction of that contract will be a good sum.

You do realise they have a lot more than Lupuzor right? I know the percentage that has the biomarker, if you read a recent rns you would too :)

Not much more I doubt. Depends on peoples patience now and if they're brave enough to see this through.

Recruitment is said to finish late July for the extension study which will take 6 months to complete, the follow on study for Lupuzor remember.

Think we'll be in for another flying week

http://www.nocanther-project.eu/index.php/project (pointed out on twitter)

Meeting: (had no idea about that)

http://magneticmicrosphere.com/meeting-twelfth-sponsors

2017 paper which brings up N6L:

http://www.mdpi.com/1420-3049/22/6/975/pdf-vor (very relevant)

"Kossatz S. et al reported the use of modified superparamagnetic iron oxide nanoparticles, suchas (MF66), Nucant 6L (MF66-N6L), doxorubicin (MF66-DOX) or both (MF66-N6LDOX), together withmagnetic hyperthermia, for treatment of breast cancer. The results showed that MF66-DOX, andMF66-N6LDOX combined with hyperthermia, were more toxic to breast cancer cells than eachcorresponding NP with ligands. There was significant inhibition of tumor growth and, in many cases,complete disruption"

(Efficient treatment of breast cancer xenografts with multifunctionalizediron oxide nanoparticles combining magnetic hyperthermia and anti-cancer drug delivery 2015)

https://www.dddmag.com/article/2018/07/novel-protein-inhibitors-could-enhance-immunotherapy-response-patients-cancer

I really don't think N6L is gonna be shelved for long will be a amazing addition to combination therapys. It allows tumours to be targeted quicker increases their vascularity in order for them to be destroyed faster.

I've put research notes up on it previously but here's the most recent paper on it in relation to protein interference within leukaemia:

https://www.sciencedirect.com/science/article/pii/S0304383517306754

https://www.onclive.com/conference-coverage/cf-hem-2018/immunotherapy-at-the-forefront-of-all-treatment-expert-says

Yup and it's not me good start to the week considering it's deados here normally

http://www.foxnews.com/health/2018/07/12/california-woman-denied-manicure-over-lupus-scars-says-ive-never-felt-more-like-leper.html

If only there were a non-immunsupressive treatment like Lupuzor. I can see why they would deny manicure if she was flared up, plus due to the lack of a immune system she could potentially catch anything at the salon if skin was damaged.

If they will produce some proprietary cannabis/spice blend for seasoning as lgc capital are into that kinda thing.

That was a nice day good way to finish the week. Seems like it moves up a step on 1.5-2m buy. I imagine that will get slimmer as the shares become non-existent. Can't be many left now.